Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 26, Issue 6, 2015, Pages 305-312

  Zhanel, George G ^a,b   Walkty, Andrew J ^a   Karlowsky, James A ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Clostridium difficile; Fidaxomicin; Infection; Recurrence; Treatment

Indexed keywords

BACTERIAL DNA; BACTERIAL ENZYME; FIDAXOMICIN; RNA POLYMERASE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COLON FLORA; COST UTILITY ANALYSIS; CROSS RESISTANCE; DNA TEMPLATE; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG FECES LEVEL; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; SYSTEMATIC REVIEW;

EID: 84952763674     PISSN: 17129532     EISSN: 19181493     Source Type: Journal    
DOI: 10.1155/2015/934594     Document Type: Article

References (74)

1. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:413-55.
2. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302-7.
3. Louie TJ, Gerson M, Grimard D, et al. Results of a phase III trial clinical trial comparing tolevar, vancomycin and metronidazole in patient with Clostridium difficile-associated diarrhea (CDAD). 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, September 17-20, 2007. (Abst K-425a).
4. Bouza E, Dryden M, Mohammed R, et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea. 18th European Congress of Clincal Microbiology and Infectious Diseases (ECCMID). Barcelona, April 19-22, 2008. (Abst O464).
5. Johnson S, Louie TJ, Gerding D, et al. Vancomycin metronidazole or tolevamer for Clostridium difficile infection: Results from two multinational randomized controlled trials. Clin Infect Dis 2014;59:345-54.
6. Wilcox MH. The trials and tribulations of treating Clostridium difficile infection - one step backward one step forward but still progress. Clin Infect Dis 2014;59:355-7.
7. Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiol 2010;156:3354-9.
8. Venugopal AA, Johnson S. Fidaxomicin: A novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis 2012;54:568-74.
9. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 1995;44:1-13.
10. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health Syst Pharm 1998;55:1407-11.
11. Al-Nassir WN, Sethi AK, Li Y, et al. Both oral metronidazole and oral vancomycin promote overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008;52:2403-6.
12. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficileassociated disease: Old therapies and new strategies. Lancet Infect Dis 2005;5:549-57.
13. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422-31.
14. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12:281-9.
15. Cornely OA, Miller MA, Fantin B, et al. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol 2013;31:2493-9.
16. Mullane KM, Cornely OA, Crook DW, et al. Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol 2013;38:1-11.
17. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011;53:440-7.
18. Louie TJ, Miller MA, Crook DW, et al. Effect of age on treatment outcomes in Clostridium difficile infection. J Am Geriatr Soc 2013;61:222-30.
19. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: Fidaxomicin versus vancomycin. Clin Infect Dis 2012;55(S2):S154-61.
20. DIFICID® Product Monograph. Optimer Pharmaceuticals, Inc. 2013.
21. Johnson AP. Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. Curr Opin Investig Drugs 2007;8:168-73.
22. Osburne MS, Sonenshein AL. Inhibition by lipiarmycin of bacteriophage growth in Bacillus subtilis. J Virol 1980;33:945-53.
23. Artsimovitch I, Seddon J, Sears P. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clin Infect Dis 2012;55(Suppl 2):S127-31.
24. Babakhani F, Seddon J, Sears P. Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile. Antimicrob Agents Chemother 2014;58:2934-7.
25. Gualtieri M, Villain-Guillot P, Latouche J, et al. Mutation in the Bacillus subtilis RNA polymerase β' subunit confers resistance to lipiarmycin. Antimicrob Agents Chemother 2006;50:401-2.
26. Wostem MM. Eubacterial sigma-factors. FEMS Microbiol Rev 1998;22:127-50.
27. Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother 2008;52:4163-5.
28. Kuehne SA, Dempster AW, Heeg D, et al. Use of allelic exchange to characterize the impact of rpoB/C mutations on fitness of Clostridium difficile and sensitivity to fidaxomicin. 23rd European Congress of Clincal Microbiology and Infectious Diseases (ECCMID). Berlin, April 27-30, 2013.
29. Seddon J, Babakhani F, Sears P. Mutant prevention concentration of fidaxomicin for Clostridium difficile. 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, September 9-12, 2012. (Abstr A-1274).
30. Goldstein EJC, Citron DM, Sears P, et al. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother 2011;55:5194-9.
31. Goldstein EJC, Babakhani F, Citron DM. Antimicrobial activities of fidaxomicin. Clin Infect Dis 2012;55(Suppl 2):S143-8.
32. Babakhani F, Gomez A, Robert N, Sears P. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob Agents Chemother 2011a;55:4427-9.
33. Leeds JA, Sachdeva M, Mullin S, et al. in vitro selection via serial passage of Clostridium difficile mutants with reduced susceptibility to fidaximicin or vancomycin. J Antimicrob Chemother 2014;69:41-4.
34. Gerber M, Ackermann G. OPT-80 a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infection: A review. Exp Opin Investig Drugs 2008;17:51-3.
35. Swanson RN, Hardy DJ, Shipkowitz NL, et al. In vitro and in vivo evaluation of tiacumicius B and C against Clostridium difficile. Antimicrob Agents Chemother 1991;35:1106-11.
36. Theriault RJ, Karwowski TP, Jackson M, et al. Tiacumicins a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity. J Antibiotic (Tokyo) 1987;40:567-74.
37. Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocyclic, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004;48:4430-4.
38. Finegold SM, Molitoris D, Vaisanen ML, et al. In vitro activities of OPT-80 and comparator drugs against anaerobic bacteria. Antimicrob Agents Chemother 2004;48:4898-902.
39. Beidenbach DI, Ross JE, Putnam SD, Jones RN. In vitro activity of fidaxomicin (OPT80) tested against contemporary isolates of Staphylococcus spp. and Enterococcus spp. Antimicrobial Agents Chemother 2010;54:2273-5.
40. Babakhani F, Seddon J, Robert N, et al. Narrow spectrum activity and low fecal binding of OPT-80 and its major hydrolysis metabolite (OP- 1118). 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, September 17 to 20, 2007.
41. Citron DM, Tyrrell KL, Merriam V, Goldstein EJC. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrob Agents Chemother 2012;56:2493-503.
42. Hecht DW, Galang MA, Sambol SP, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51:2716-9.
43. Citron DM, Babakhani F, Goldstein EJ, et al. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Anaerobe 2009;15:234-6.
44. Rashid MU, Dalhoff A, Weintraub A, Nord CE. In vitro activity of MCB3681 against Clostridium difficile strains. Anaerobe 2014;28:216-9.
45. Goldstein EJC, Citron DM, Tyrrell KL, Merriam CV. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 Gram-positive and Gram-negative aerobic and anaerobic intestinal flora isolates. Antimicrob Agents Chemother 2013;57:4872-6.
46. Louie T, Miller M, Donskey C, et al. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009;53:223-8.
47. Louie TJ, Cannon K, Byrne B, et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin Infect Dis 2012;55(Suppl 2):S132-42.
48. Babakhani F, Seddon J, Robert N, et al. Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile. Antimicrob Agents Chemother 2010;54:2674-6.
49. Sears P, Crook DW, Louie TJ, Miller MA, Weiss K. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis 2012;55(Suppl 2):S116-20.
50. Seddon J, Babakhani F, Sears P. Mutant prevention concentration of fidaxomicin for Clostridium difficile. 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, September 9-12, 2012. (Abstr. A-1274).
51. Babakhani F, Gomez A, Robert N, Sears P. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol 2011;60:1213-7.
52. Babakhani F, Bouillaut L, Sears P, et al. Fidaxomicin inhibits toxin production in Clostridium difficile. J Antimicrob Chemother 2013;68:515-22.
53. Koon HW, Ho S, Hing TC, et al. Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum. Antimicrob Agents Chemother 2014;58:4642-50.
54. Babakhani F, Bouillaut L, Gomez A, et al. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis 2012;55(Suppl 2):S162-9.
55. Allen CA, Babakhani F, Sears P, et al. Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores. Antimicrob Agents Chemother 2013;57:664-7.
56. Chilton CH, Crowther GS, Freeman J, et al. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure. J Antimicrob Chemother 2014;69:451-62.
57. Nerandzic MM, Mullane K, Miller MA, et al. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 2012;55(Suppl 2):S121-6.
58. Mullane KM. Fidaxomicin in Clostridium difficile infection: Latest evidence and clinical guidance. Ther Adv Chronic Dis 2014;5:69-84.
59. Esmaily-Fard A, Tverdek FP, Crowther, et al. The use of fidaxomicin for treatment of relapsed Clostridium difficile infections in patients with cancer. Pharmacother 2014;34:1220-5.
60. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003;139:137-47.
61. Vargo CA, Bauer KA, Mangino JE, Johnston JEW, Goff DA. An antimicrobial stewardship program's real-world experience with fidaxomicin for treatment of Clostridium difficile infection: A case series. Pharmacotherapy 2014;34:901-9.
62. Eiland EH, Sawyer AJ, Massie NL. Fidaxomicin use and clinical outcomes for Clostridium difficile-associated diarrhea. Infect Dis Clin Pract 2015;23:32-5.
63. Clutter DS, Dubrovskaya Y, Merl MY, Teperman L, Press R, Safdar A. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 2013;57:4501-5.
64. Penziner S, Dubrovskaya Y, Press R, Safdar A. Fidaxomicin therapy in critically ill patients with Clostridium difficile infection. Antimicrob Agents Chemother 2015;59:1776-81.
65. Soriano MM, Danziger LH, Gerding DN, Johnson S. Novel fidaxomicin treatment regimens for patients with multiple Clostridium difficile infection recurrences that are refractory to standard therapies. Open Forum Infect Dis 2014 Aug 25;1:ofu069.
66. Weiss K, Allgren RL, Sellers S. Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infection. Clin Infect Dis 2012;55(Suppl 2):S110-5.
67. Iarikov DE, Alexander J, Nambiar S. Hypersensitivity reactions associated with fidaxomicin use. Clin Infect Dis 2014;58:537-9.
68. Cornely OA, Nathwani D, Ivanescu C, et al. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: A meta-analysis and indirect treatment comparison. J Antimicrob Chemother 2014;69:2892-900.
69. Eyre DW, Babakhani F, Griffiths D, et al. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for peventing reinfection and relapse of infection with Clostridium difficile. J Infect Dis 2014;209:1446-51.
70. Wagner M, Lavoie L, Goetghebeur M. Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada. Can J Infect Dis Med Microbiol 2014;25:87-94.
71. Stranges PM, Hutton DW, Collins CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health 2013;16:297-304.
72. Nathwani D, Cornely OA, Van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IAO. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother 2014;69:2901-12.
73. Debast SB, Bauer MP, Kuijper EJ, on behalf of the Committee. European Society of Clinical Microbiology and Infectious Diseases: Update on the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014;20(Suppl 2):1-26.
74. Wilcox MH. Updated guidance on the management and treatment of Clostridium difficile infection. (Accessed September 17, 2014).